data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
Watch
YouTube
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
VistaGen Therapeutics
(NASDAQ:VTGN)
$0.175
0.0041[2.40%]
At close: Aug 11
$0.1561
-0.0189[-10.80%]
After Hours: 7:32PM EDT
Day High/Low0.17 - 0.19
52 Week High/Low0.14 - 2.11
Open / Close0.17 / 0.18
Float / Outstanding206.4M / 206.6M
Vol / Avg.22.7M / 8.7M
Mkt Cap36.2M
P/E-
50d Avg. Price0.73
Div / Yield-
Payout Ratio-
EPS-0.09
Total Float206.4M

VistaGen Therapeutics (NASDAQ:VTGN), Quotes and News Summary

VistaGen Therapeutics (NASDAQ: VTGN)

Day High/Low0.17 - 0.19
52 Week High/Low0.14 - 2.11
Open / Close0.17 / 0.18
Float / Outstanding206.4M / 206.6M
Vol / Avg.22.7M / 8.7M
Mkt Cap36.2M
P/E-
50d Avg. Price0.73
Div / Yield-
Payout Ratio-
EPS-0.09
Total Float206.4M
Sector: Health Care.Industry: Biotechnology
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Read More

Earnings

see more
Q2 2023Est.ActualSurprise
EPS
(EXPECTED)2022-11-09
REV
Q1 2023Est.ActualSurprise
EPS-0.100
REV310.100K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

VistaGen Therapeutics Questions & Answers

Q
How do I buy VistaGen Therapeutics (VTGN) stock?
A

You can purchase shares of VistaGen Therapeutics (NASDAQ: VTGN) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are VistaGen Therapeutics's (VTGN) competitors?
Q
What is the target price for VistaGen Therapeutics (VTGN) stock?
A

The latest price target for VistaGen Therapeutics (NASDAQ: VTGN) was reported by Maxim Group on Tuesday, July 26, 2022. The analyst firm set a price target for 0.00 expecting VTGN to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

Q
Current Stock Price for VistaGen Therapeutics (VTGN)?
A

The stock price for VistaGen Therapeutics (NASDAQ: VTGN) is $0.175 last updated Today at August 11, 2022, 8:00 PM UTC.

Q
Does VistaGen Therapeutics (VTGN) pay a dividend?
A

There are no upcoming dividends for VistaGen Therapeutics.

Q
When is VistaGen Therapeutics (NASDAQ:VTGN) reporting earnings?
A

VistaGen Therapeutics’s Q2 earnings are confirmed for Wednesday, November 9, 2022.

Q
Is VistaGen Therapeutics (VTGN) going to split?
A

There is no upcoming split for VistaGen Therapeutics.

Q
What sector and industry does VistaGen Therapeutics (VTGN) operate in?
A

VistaGen Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.